Mount Sinai Selects Exemplar LIMS for Genomics Core Facility
News May 07, 2013
Exemplar LIMS™ has been selected as the lab management solution for the Genomics Core Facility at The Mount Sinai Medical Center in New York. Sapio's LIMS system will track multiple next-generation sequencing (NGS) platform workflows from request through secondary analysis.
The Mount Sinai Genomics Core Facility is a CLIA-certified laboratory, and Exemplar LIMS is used to perform the detailed tracking required for NGS clinical sample processing. The Exemplar LIMS system enables the Mount Sinai user community to submit samples online and track the sequencing process. Also, Exemplar LIMS offers automatic initiation of primary analysis at the end of the sequencing process and provides frequent progress updates to users. Exemplar also generates billing information that is passed onto the Mount Sinai financial system.
"Mount Sinai is a world leader in the genomics domain at the forefront of NGS research, with one of the few labs certified for processing clinical NGS samples in the US," said Kevin Cramer, VP at Sapio Sciences. "We look forward to working with the Mount Sinai team to streamline their lab operations while tracking the complete NGS pipeline."
"We selected Exemplar LIMS as it is modular in structure and configurable to expand and adapt with rapidly changing NGS and other genomic technologies," said Milind Mahajan, Ph.D., Director of the Genomics Core Facility at Mount Sinai. "Exemplar supports our CLIA sequencing and cutting-edge biological research to develop multi-scale models of disease."
Mount Sinai will also utilize Exemplar's Materials Management capability for reagent usage tracking. Sapio's LIMS software will be deployed on Apple iPads™ using Exemplar LIMS for Tablets solution. This enables lab technicians to take the LIMS with them as they move around the laboratory improving LIMS usability and lab technician efficiency.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
The architecture of each person’s brain is unique, and differences may influence how quickly people can complete various cognitive tasks.o learn more, scientists are developing a new tool — computational models of the brain — to simulate how the structure of the brain may impact brain activity and, ultimately, human behavior.READ MORE